Por favor, use este identificador para citar o enlazar este ítem:
https://repositorio.uca.edu.ar/handle/123456789/15119
Título : | Interethnic variability in CYP2D6, CYP2C9, and CYP2C19 genes and predicted drug metabolism phenotypes among 6060 Ibero- and native americans: RIBEF-CEIBA Consortium Report on population pharmacogenomics | Autor : | Naranjo, María Eugenia G. Rodrigues Soares, Fernanda Peñas Lledó, Eva M. Tarazona Santos, Eduardo Fariñas, Humberto Rodeiro, Idania Terán, Enrique Grazina, Manuela Moya, Graciela E. López López, Marisol Sarmiento, Alba P. Calzadilla, Luis R. Ramírez Roa, Ronald Ortiz López, Rocío Estévez Carrizo, Francisco E. Sosa Macías, Martha Barrantes, Ramiro LLerena, Adrián |
Palabras clave : | FARMACOGENETICA; GENOTIPOS; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6 | Fecha de publicación : | 2018 | Editorial : | Mary Ann Liebert | Cita : | Naranjo, M.E.G., et al. Interethnic variability in CYP2D6, CYP2C9, and CYP2C19 genes and predicted drug metabolism phenotypes among 6060 Ibero- and native americans: RIBEF-CEIBA Consortium Report on population pharmacogenomics [en línea]. OMICS: A Journal of Integrative Biology. 2018, 22(09) doi:10.1089/omi.2018.0114 Disponible en: | Resumen : | Abstarct Pharmacogenetic variation in Latin Americans is understudied, which sets a barrier for the goal of global precision medicine. The RIBEF-CEIBA Network Consortium was established to characterize interindividual and between population variations in CYP2D6, CYP2C9, and CYP2C19 drug metabolizing enzyme genotypes, which were subsequently utilized to catalog their "predicted drug metabolism phenotypes" across Native American and Ibero American populations. Importantly, we report in this study, a total of 6060 healthy individuals from Ibero-America who were classified according to their self-reported ancestry: 1395 Native Americans, 2571 Admixed Latin Americans, 96 Afro-Latin Americans, 287 white Latin Americans (from Cuba), 1537 Iberians, and 174 Argentinean Ashkenazi Jews. Moreover, Native Americans were grouped into North-, Central-, and South Amerindians (from Mexico, Costa Rica, and Peru, respectively). All subjects were studied for the most common and functional CYP2D6, CYP2C9, and CYP2C19 allelic variants, and grouped as genotype-predicted poor or ultrarapid metabolizer phenotypes (gPMs and gUMs, respectively). Native Americans showed differences from each ethnic group in at least two alleles of CYP2D6, CYP2C9, and CYP2C19. Native Americans had higher frequencies of wild-type alleles for all genes, and lower frequency of CYP2D6*41, CYP2C9*2, and CYP2C19*17 (p < 0.05). Native Americans also showed less CYP2C19 gUMs than the rest of the population sample. In addition, differences within Native Americans (mostly North vs. South) were also found. The interethnic differences described supports the need for population-specific personalized and precision medicine programs for Native Americans. To the best of our knowledge, this is the largest study carried out in Native Americans and other Ibero-American populations analyzing CYP2D6, CYP2C9, and CYP2C19 genetic polymorphisms. Population pharmacogenomics is a nascent field of global health and warrants further research and education. | URI : | https://repositorio.uca.edu.ar/handle/123456789/15119 | Disciplina: | MEDICINA | DOI: | 10.1089/omi.2018.0114 | Derechos: | info:eu-repo/semantics/closedAccess |
Aparece en las colecciones: | Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | Usuarios registrados haga click en: Login |
---|---|---|---|---|
Interethnic-variability.pdf | 373,76 kB | Adobe PDF | ||
thumb.jpg | 444,37 kB | JPEG | Visualizar/Abrir |
Visualizaciones de página(s)
59
comprobado en 27-abr-2024
Descarga(s)
16
comprobado en 27-abr-2024
Google ScholarTM
Consultar
Altmetric
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons